Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Metagenomi (MGX) to $20 from $25 and keeps an Overweight rating on the shares. With key initiatives progressing on track, the firm looks forward to the final NHP FVIII durability analysis in the first half of 2025 as well as updates on Ionis (IONS) collaboration programs and preclinical PoC for a secreted protein deficiency target this year.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue